S1R Stock Overview
Shanghai Pharmaceuticals Holding Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Shanghai Pharmaceuticals Holding Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥1.58 |
| 52 Week High | CN¥1.63 |
| 52 Week Low | CN¥1.11 |
| Beta | 0.29 |
| 1 Month Change | 7.48% |
| 3 Month Change | 38.60% |
| 1 Year Change | 28.46% |
| 3 Year Change | 4.39% |
| 5 Year Change | -7.06% |
| Change since IPO | -9.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| S1R | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -1.3% | -3.5% | -2.6% |
| 1Y | 28.5% | 15.6% | 6.9% |
Return vs Industry: S1R exceeded the German Healthcare industry which returned 15.6% over the past year.
Return vs Market: S1R exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| S1R volatility | |
|---|---|
| S1R Average Weekly Movement | 7.5% |
| Healthcare Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: S1R's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: S1R's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 49,234 | Bo Shen | www.sphchina.com |
Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestive system, immune metabolism, motor neuron disease, endocrinology, cardiovascular, psychoneurotic, neoplasm, autoimmunity, systemic anti-infection, mental nerve, anti-tumor, oncology, respiratory system, nervous system, auto-immunity, hypertension, neuromyelitis, diabetes, anticholinesterase, polypeptide hormones uterine tonic, antihistamine, anti-inflammatory, anesthetic, immunomodulatory, antiviral, reflux esophagitis, analgesics, weight management, malignant peritoneal effusion, ulcerative colitis, myasthenia gravis, burn injury, anticoagulant, anti-epileptic, anticonvulsant, Alzheimer’s, and inflammatory bowel diseases.
Shanghai Pharmaceuticals Holding Co., Ltd Fundamentals Summary
| S1R fundamental statistics | |
|---|---|
| Market cap | €9.32b |
| Earnings (TTM) | €528.77m |
| Revenue (TTM) | €35.78b |
19.7x
P/E Ratio0.3x
P/S RatioIs S1R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S1R income statement (TTM) | |
|---|---|
| Revenue | CN¥272.42b |
| Cost of Revenue | CN¥242.27b |
| Gross Profit | CN¥30.14b |
| Other Expenses | CN¥26.12b |
| Earnings | CN¥4.03b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.09 |
| Gross Margin | 11.07% |
| Net Profit Margin | 1.48% |
| Debt/Equity Ratio | 58.2% |
How did S1R perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield38%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:16 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Pharmaceuticals Holding Co., Ltd is covered by 52 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xing Qiu Lin | AJ Securities Co., Ltd |
| Zhi Xue Diao | Avic Securities Co., Ltd |
| Derrick Sun | BNP Paribas Securities (Asia) |